Alnylam Pharmaceuticals
ALNY
#871
Rank
NZ$49.64 B
Marketcap
NZ$371.00
Share price
-0.41%
Change (1 day)
-49.26%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$6.60

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$6.44. In 2025 the company made an earnings per share (EPS) of NZ$3.06.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.60115.8%
2025NZ$3.06
2023NZ-$6.00-62%
2022NZ-$15.7929.03%
2021NZ-$12.24-3.36%
2020NZ-$12.66-8.48%
2019NZ-$13.837.67%
2018NZ-$12.8539.74%
2017NZ-$9.1912.94%
2016NZ-$8.1438.84%
2015NZ-$5.86-32.88%
2014NZ-$8.74259.44%
2013NZ-$2.43-31.25%
2012NZ-$3.53

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$11.93 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$4.35-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$72.28 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$0.97-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.24-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.46-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.33-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$1.38-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA